SCHEMBL1946003

SCHEMBL1946003

Cc1ccc(S(=O)(=O)NC(=O)N2CCc3ccc(NS(=O)(=O)c4ccc(C)cc4)cc3CC2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA1 Q09470 10/20 1.00
KCNAB1 Q14722 10/20 1.00
ALDH1A1 P00352 2/20 0.65
LMNA P02545 1/20 0.65
THRB P10828 1/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
L3MBTL1 Q9Y468 1/20 0.65
HPGD P15428 1/20 0.61
HSD17B10 Q99714 1/20 0.61
KMT2A Q03164 1/20 0.56
DPP4 P27487 1/20 0.55
DRD2 P14416 2/20 0.54
HTR2A P28223 2/20 0.54
HTR2C P28335 2/20 0.54
DRD3 P35462 2/20 0.54
HTR6 P50406 2/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2D6 P10635 1/20 0.54
CYP2C9 P11712 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1944493 0.96 KCNA1 (0.92) KCNA1KCNAB1ALDH1A1LMNATHRB
SCHEMBL1946008 0.93 KCNA1 (1.00) KCNA1KCNAB1ALDH1A1LMNATHRB
SCHEMBL1945507 0.89 KCNA1 (1.00) KCNA1KCNAB1ALDH1A1LMNAHPGD
SCHEMBL1946194 0.89 KCNA1 (0.84) KCNA1KCNAB1ALDH1A1LMNATHRB
SCHEMBL1947342 0.88 KCNA1 (0.82) KCNA1KCNAB1ALDH1A1LMNATHRB
SCHEMBL1946344 0.88 KCNA1 (0.78) KCNA1KCNAB1ALDH1A1LMNATHRB
SCHEMBL1945005 0.85 KCNA1 (0.92) KCNA1KCNAB1ALDH1A1LMNAHPGD
SCHEMBL6163822 0.84 KCNA1 (0.72) KCNA1KCNAB1ALDH1A1LMNATHRB
SCHEMBL1945192 0.82 KCNA1 (0.92) KCNA1KCNAB1ALDH1A1LMNASMN1; SMN2
SCHEMBL1947206 0.82 KCNA1 (1.00) KCNA1KCNAB1ALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110130383-A1 Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases LECTUS THERAPEUTICS LIMITED (GB) 2011-06-02 US claimed
US-20090318423-A1 Ion Channel Modulators & Uses Thereof LECTUS THERAPEUTICS LIMITED (GB) 2009-12-24 US claimed
US-20110130383-A1 Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases LECTUS THERAPEUTICS LIMITED (GB) 2011-06-02 US disclosed
US-20110130383-A1 Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases LECTUS THERAPEUTICS LIMITED (GB) 2011-06-02 US disclosed
US-20090318423-A1 Ion Channel Modulators & Uses Thereof LECTUS THERAPEUTICS LIMITED (GB) 2009-12-24 US disclosed
US-20090318423-A1 Ion Channel Modulators & Uses Thereof LECTUS THERAPEUTICS LIMITED (GB) 2009-12-24 US disclosed
US-20090318423-A1 Ion Channel Modulators & Uses Thereof LECTUS THERAPEUTICS LIMITED (GB) 2009-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318423-A1 Ion Channel Modulators & Uses Thereof KCNH3, KCNN3, KCNH2 KCNA1 26/4885KCNAB1 40/4885ALDH1A1 1965/4885
US-20110130383-A1 Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases HCAR2, HCAR1, SCN7A KCNA1 167/4885KCNAB1 98/4885ALDH1A1 2831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.